CN113995744A - Composition and antibacterial application thereof - Google Patents

Composition and antibacterial application thereof Download PDF

Info

Publication number
CN113995744A
CN113995744A CN202111195294.4A CN202111195294A CN113995744A CN 113995744 A CN113995744 A CN 113995744A CN 202111195294 A CN202111195294 A CN 202111195294A CN 113995744 A CN113995744 A CN 113995744A
Authority
CN
China
Prior art keywords
acid
composition
glycine
hippuric
valine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202111195294.4A
Other languages
Chinese (zh)
Other versions
CN113995744B (en
Inventor
朱绍和
陈丽
宋坤坪
田雪晨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wenzhou Lien Biotechnology Co.,Ltd.
Original Assignee
Wenzhou Kean University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wenzhou Kean University filed Critical Wenzhou Kean University
Priority to CN202111195294.4A priority Critical patent/CN113995744B/en
Priority to LU102887A priority patent/LU102887B1/en
Publication of CN113995744A publication Critical patent/CN113995744A/en
Priority to PCT/CN2022/124947 priority patent/WO2023061416A1/en
Application granted granted Critical
Publication of CN113995744B publication Critical patent/CN113995744B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/02—Saturated carboxylic acids or thio analogues thereof; Derivatives thereof
    • A01N37/04—Saturated carboxylic acids or thio analogues thereof; Derivatives thereof polybasic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/06—Unsaturated carboxylic acids or thio analogues thereof; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/36—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a singly bound oxygen or sulfur atom attached to the same carbon skeleton, this oxygen or sulfur atom not being a member of a carboxylic group or of a thio analogue, or of a derivative thereof, e.g. hydroxy-carboxylic acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
    • A01N37/46—N-acyl derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/42—Preservation of non-alcoholic beverages
    • A23L2/44—Preservation of non-alcoholic beverages by adding preservatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
    • A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
    • A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
    • A23L3/3463—Organic compounds; Microorganisms; Enzymes
    • A23L3/3481—Organic compounds containing oxygen
    • A23L3/3508—Organic compounds containing oxygen containing carboxyl groups
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
    • A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
    • A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
    • A23L3/3463—Organic compounds; Microorganisms; Enzymes
    • A23L3/3526—Organic compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/362—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/48—Medical, disinfecting agents, disinfecting, antibacterial, germicidal or antimicrobial compositions
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D7/00—Compositions of detergents based essentially on non-surface-active compounds
    • C11D7/22—Organic compounds
    • C11D7/26—Organic compounds containing oxygen
    • C11D7/265—Carboxylic acids or salts thereof
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D7/00—Compositions of detergents based essentially on non-surface-active compounds
    • C11D7/22—Organic compounds
    • C11D7/32—Organic compounds containing nitrogen
    • C11D7/3245—Aminoacids
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D7/00—Compositions of detergents based essentially on non-surface-active compounds
    • C11D7/22—Organic compounds
    • C11D7/32—Organic compounds containing nitrogen
    • C11D7/3263—Amides or imides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dentistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to a composition and its antibacterial application, used for human body and environment application, can reduce the reproduction trend of its existing microorganism, the composition comprises: one or more of malic acid, hippuric acid, fumaric acid, glycine, succinic acid, L-valine and citric acid.

Description

Composition and antibacterial application thereof
Technical Field
The invention relates to the technical field of medicines, in particular to a composition and antibacterial application thereof.
Background
The pangolin scales are used in the Xianfang Huoming drink in the 'woman good prescription' written by Song Dynasty Chen Ming Shuang, and the whole formula has the effects of clearing heat and removing toxicity, eliminating swelling and dissipating hard mass, activating blood and relieving pain and the like, and has the symptoms of local inflammation and hot pain at the beginning of sore and ulcer. Pangolin scales recorded in Ben Cao gang mu of Ming Dynasty Li Shizhen records that it can eliminate phlegm, malaria, chills and fever, wind-arthralgia, rigidity and pain, dredge meridians, relieve pain and swelling, expel pus and blood, dredge orifices and kill parasites. The formula of "Fu Fang" refers to "diarrhea with urgency", Chuan shan Jia and Ge Qiao powder are stir-baked and ground into powder. As can be seen from the above ancient medical records, pangolin scales are used to treat diseases that modern medicine believes to be caused by bacterial infections. Guo Yi et al reported in the reports of Hunan institute of Traditional Chinese Medicine (TCM) report that pangolin water decoction has antibacterial effect on 11 kinds of bacteria such as Escherichia coli, wherein the main component of water decoction is squama Manis.
However, as pangolins are extremely endangered in modern society, 8 pangolins are listed in red famous records of endangered species in the world natural protection alliance (IUCN)2014, and are listed in the level I protective animals in CITES appendix of Washington convention 2016, and global trade is prohibited. China is the contracting country of International trade Convention (CITES) on endangered wild animal and plant species. Meanwhile, in 2020, Pangolin scales are excluded from the Chinese pharmacopoeia and used as the medicine. Therefore, the ingredients or ingredient compositions for inhibiting the flora in the squama of the pangolin are researched, and the squama of the pangolin is artificially synthesized to be used as a substitute, so that the relevant treatment scheme for replacing the ingredients of the pangolin is not influenced, and the pangolin of the endangered animal can be protected.
In the prior art, an organic acid is used in various fields as an organic acid additive, wherein citric acid is used as the organic acid which is used most frequently for preservation and flavor addition. Chinese patent with publication number CN108670897B relates to a high-efficiency bacteriostatic wet tissue composition and a preparation method thereof. The preparation raw materials of the efficient antibacterial wet tissue composition comprise, by weight, 1-6 parts of ethanol, 0.5-3 parts of butanediol, 0.2-0.6 part of solubilizer, 0.01-0.02 part of menthol, 0.1-0.12 part of essence, 0.5-1.0 part of tea extract, 0.5-1.0 part of olive leaf extract, nano-silver, 0.5-1.0 part of purslane extract, 0.1-0.2 part of citric acid, 0.05-0.15 part of sodium citrate and 0.01-0.05 part of phenoxyethanol. The composition contains organic acid citric acid as antibacterial component, wherein phenoxyethanol is used for promoting citric acid dissolution. However, the existing organic acids are various, and the bacteriostatic effect of citric acid cannot reach the highest bacteriostatic efficiency.
In the prior art, various weakly acidic bacteriostatic and preservative effects are proved, but the application of organic acids for inhibiting the effects of escherichia coli and staphylococcus aureus which have the most extensive and frequent effects on human diseases is not found.
According to the experiment, the metabolite composition for inhibiting bacteria in the squama manitis is explored through the component research of the squama manitis with good antibacterial effect, so that the antibacterial effect of replacing the squama manitis with multi-combination weak acid is realized.
Furthermore, on the one hand, due to the differences in understanding to the person skilled in the art; on the other hand, since the applicant has studied a great deal of documents and patents in the process of making the present invention, the extent of which is not limited to the details and contents listed, it is by no means the present invention has all the features of the prior art but the present invention has all the features of the prior art, and the applicant reserves the right to increase the related prior art in the background.
Disclosure of Invention
In view of the deficiencies of the prior art, the present invention provides a composition. Is used for human body or environment in which human body is located, and can reduce the propagation tendency of microorganism existing in the environment. The composition comprises: one or more of malic acid, hippuric acid, fumaric acid, glycine, succinic acid, L-valine and citric acid.
Preferably, the ingredients in the composition comprise: (1) malic acid; (2) hippuric acid; (3) optionally at least one group of weakly acidic components of: 1) glycine; 2) succinic acid and/or L-valine.
Preferably, the ingredients in the composition comprise: (1) malic acid; (2) hippuric acid; (3) optionally at least one group of weakly acidic components of: 1) fumaric acid and/or glycine; 2) succinic acid and/or L-valine.
According to a preferred embodiment, the first component consisting of malic acid, hippuric acid, succinic acid, L-valine is co-formulated with the second component consisting of fumaric acid or succinic acid to form a composition having an inhibitory effect on the growth of microorganisms.
The technical scheme has the advantages that: compared with the application of single organic acid, the organic acid combination formed by multiple combinations can form better antibacterial effect (proved by antibacterial tests) compared with the single organic acid, and different flavors of the disinfection components acting on human bodies, such as food, makeup, oral cavity cleaning and the like are formed by the combination of multiple organic acids, so that the aims of deodorization and refreshment are fulfilled. The formation and decomposition of organic acid are harmless to human body and environment, and the principle of bacteriostasis and sterilization is that small molecules enter the bacterial body and destroy the alkaline active environment in the bacterial body, thereby inhibiting the bacterial activity. The combination of the organic acids in various combinations forms a covalent structure with each other and forms bacteriostatic effects which are mutually increased, and the organic acids which are singly or multiply randomly combined and need to be added in large dose are replaced by the composition in smaller dose, thereby reducing the harm to human bodies caused by excessive intake of food additives.
According to a preferred embodiment, said composition for acting on the human body or the environment comprises malic acid, hippuric acid, glycine and citric acid, wherein the composition is capable of enhancing the fruit aroma components for acting on the environment in a manner buffering acidic organoleptic properties based on the interaction of malic acid and citric acid.
According to a preferred embodiment, the composition comprises at least malic acid, hippuric acid, glycine and citric acid, wherein the components constituting the composition are applied to the skin surface in the form of a non-newtonian fluid.
According to a preferred embodiment, the composition comprises at least malic acid, hippuric acid, glycine and fumaric acid, wherein the components constituting the composition are applied to the skin surface in the form of a non-newtonian fluid.
The technical scheme has the advantages that: drugs and cosmetics used for repairing, treating or protecting skin surfaces cannot be stably hung on the face due to the fluidity of fluid in the process of applying, but the pasty drugs are not easy to be uniformly applied due to the viscosity. The invention adopts the component form of non-Newtonian fluid, reduces the fluidity of the non-Newtonian fluid and does not change the viscosity, thereby ensuring the stability of the components attached on the face and the skin.
According to a preferred embodiment, the composition is capable of inhibiting the division of escherichia coli and staphylococcus aureus in a synergistic manner.
A composition capable of forming a cleaning ingredient of an oral cavity cleanser with an abrasive in the form of a dispersed phase, the composition being useful for inhibiting the growth of Escherichia coli and Staphylococcus aureus in the interior of the oral cavity, wherein the composition comprises one or more of malic acid, hippuric acid, fumaric acid, glycine, succinic acid, L-valine, and citric acid.
A composition for inhibiting the proliferation of Escherichia coli and Staphylococcus aureus on human skin or in food, wherein the composition comprises one or more of malic acid, hippuric acid, fumaric acid, glycine, succinic acid, L-valine and citric acid.
Antibacterial use of a composition for application as an additive in a detergent or bactericide, said composition as an additive being provided with means for releasing H+And a second composition for increasing the biocidal effect and time. The first composition comprises: one or more of malic acid, hippuric acid, fumaric acid, glycine, succinic acid, L-valine and citric acid, and the second composition comprises hydrocolloid. Wherein, inWhen the composition as an additive is applied, the first composition intervenes in the second composition and acts on the interior of the bacterial body of escherichia coli or staphylococcus aureus along with the coating of the second composition on the escherichia coli or staphylococcus aureus carried by the object of detergent or bactericide application.
Antibacterial use of a composition for inhibiting the growth of bacteria in tissue inflammation caused by bacterial infection, said medicament comprising as essential components: one or more of malic acid, hippuric acid, fumaric acid, glycine, succinic acid, L-valine and citric acid.
Detailed Description
The invention relates to a bacteriostatic composition which can achieve the most effective inhibitory action on microorganisms represented by escherichia coli and staphylococcus aureus.
Organic acids used for bacteriostasis include Fumaric acid (Fumaric acid), Succinic acid (Succinic acid), L-Valine (L-Valine), Malic acid (Malic acid), Citric acid (Citric acid), Glycine (Glycine), and Hippuric acid (Hippuric acid). The proportion of the extract is consistent with the content of squama Manis, wherein in the total extract (CV), fumaric acid accounts for 0.1%, succinic acid accounts for 0.4%, L-valine accounts for 1.3%, malic acid accounts for 1.2%, citric acid accounts for 0.2%, glycine accounts for 0.1%, and hippuric acid accounts for 0.3%. Preferably, the above ratio is adjustable and effective.
The microorganisms referred to herein can comprise gram-negative bacteria, gram-positive bacteria, or comprise staphylococcus aureus as a representative of pathogenic staphylococci, coliform bacteria as a representative of conditional pathogenic bacteria or other pathogenic bacteria, such as mycobacterium tuberculosis.
The organic acids used in the experiments and constituting the components of the composition of the present invention are all artificially synthesized organic acids.
By the special content proportion of the composition, the better antibacterial effect is achieved compared with that of a single or few compositions with the same volume.
Example 1
Bacteriostatic tests were carried out based on the Minimum Inhibitory Concentration (MIC) method, and the above-described antibacterial metabolites were used for the detection of Minimum Inhibitory Concentrations (MIC) of Escherichia coli (e.coli; Escherichia coli) and Staphylococcus aureus (s.aureus; Staphylococcus aureus), Pseudomonas aeruginosa (p.aeruginosa; Pseudomonas aeruginosa) and Serratia marcescens (s.processes; Serratia marcocens), respectively.
(1) Experimental materials:
1) culture medium
A lysis Broth (LB; Lysogeny Broth) medium containing 10g/L of peptone, 5g/L of yeast extract and 10g/L of sodium chloride was used.
2) Antibacterial drugs:
comprises the whole composition consisting of one or more of fumaric acid, succinic acid, L-valine, malic acid, citric acid, glycine and hippuric acid.
(2) The bacteriostatic test comprises the following steps:
1) preparation of bacterial suspension
And simultaneously recovering the preserved escherichia coli representing gram-negative bacteria and staphylococcus aureus representing gram-positive bacteria. A single colony having a diameter of about 1 mm was picked up on a plate of the test bacterium which had been purified by using an inoculating loop, inoculated into 2mL of LB broth, and cultured in a biochemical incubator at 37 ℃. The enriched logarithmic phase bacterial liquid is adjusted to 0.5 McLeod's turbidimetric standard (i.e. absorbance at 625 nm is 0.08-0.10) with LB broth, and contains about 1 × 108～2×108CFU·mL-1。
2) Preparation of antibacterial medicine
Preparing the combined antibacterial agent with concentration of 4C, 2C, C, 0.5C, 0.25C, 0.125C, 0.0625C, 0.03125C by two-fold dilution method, numbering 8 sterile test tubes in sequence, and adding 1ml sterile water into 2-8 test tubes. Preparing 2ml of 4C antibacterial drug in a first test tube, adding 1ml of solution in the first test tube into a second test tube, uniformly mixing, adding 1ml of solution in the second test tube into a third test tube, and sequentially diluting.
3) MIC assay
200. mu.L of LB broth was added to column 1 of a 96-well plate as a negative control, and 180. mu.L of the prepared bacterial suspension was added to columns 2-10 to a final concentration of 1X 105CFU·mL-1. And 20 mul of sterile water is added to the column 2 to serve as a positive control group, and 20 mul of medicaments are added to the columns 3-10 respectively, wherein the final concentration of the medicaments is 0.4, 0.2, 0.1, 0.05, 0.025, 0.0125, 0.00625 and 0.003125C. The respective inoculated drug sensitive plates were placed in an incubator at 37 ℃ for 24 hours, and MIC values were measured by observing turbidity of LB broth medium and detecting OD values, and the experiment was repeated 3 times.
The results are shown in Table 1, the minimum inhibitory concentration of each metabolite on Escherichia coli and Staphylococcus aureus is obtained, the concentrated antibacterial metabolites which independently exist are summarized, and malic acid is the best inhibitory effect on Escherichia coli and Staphylococcus aureus.
Figure BDA0003302385110000051
Figure BDA0003302385110000061
TABLE 1
In order to verify the optimal effect of malic acid and the composition thereof, the experiment further performed bacteriostatic tests on malic acid and other metabolites as compositions, and the results represented by MIC values are shown in Table 2.
Figure BDA0003302385110000062
TABLE 2
Experimental results show that the MIC value of the two-component composition added with malic acid to escherichia coli and staphylococcus aureus is reduced, and the two-component composition has a higher inhibition effect on the escherichia coli and the staphylococcus aureus. Still further, random dispensing of the three compositions was performed and the bacteriostatic test was performed as shown in table 3.
Figure BDA0003302385110000063
Figure BDA0003302385110000071
TABLE 3
The combination of malic acid and fumaric acid has a weak rebound of bacteriostatic effect when combined with L-valine or citric acid, and similarly, malic acid and L-valine have the same result when combined with glycine or hippuric acid, and have a weak inhibitory effect on Escherichia coli and Staphylococcus aureus, and the MIC value rises to 0.4C. The composition formed by malic acid, hippuric acid and citric acid has optimal inhibition effect on escherichia coli, and the MIC value is 0.1C.
The experiment also carried out bacteriostatic tests on four compositions formed by distributing other metabolites and malic acid by selecting malic acid as a main component, and the results are shown in table 4.
Figure BDA0003302385110000072
Figure BDA0003302385110000081
TABLE 4
The results show that the combination of malic acid, fumaric acid, glycine and hippuric acid and the combination of malic acid, citric acid, glycine and hippuric acid are able to develop bacteriostatic effects with MIC as low as 0.1C.
In the experiment, five compositions consisting of malic acid as a main component and other metabolites are distributed to perform bacteriostasis tests, and the results are shown in table 5.
Figure BDA0003302385110000082
Figure BDA0003302385110000091
TABLE 5
The results show that malic acid, L-valine, citric acid, glycine, hippuric acid; malic acid, fumaric acid, succinic acid, L-valine, hippuric acid; the three compositions of malic acid, fumaric acid, L-valine, glycine and hippuric acid can have an inhibitory effect on escherichia coli with an MIC value of 0.1C. The composition comprises malic acid, succinic acid, L-valine, glycine and hippuric acid; malic acid, fumaric acid, L-valine, citric acid, hippuric acid; malic acid, fumaric acid, citric acid, glycine, hippuric acid; malic acid, succinic acid, L-valine, citric acid, hippuric acid; any one group of malic acid, succinic acid, citric acid, glycine and hippuric acid can have an inhibitory effect of 0.1C on Escherichia coli and Staphylococcus aureus. Compared with the prior art that a single organic acid or two organic acids are used as additives, the bacteriostatic effect of the bacteriostatic additive is not as good as that of a bacteriostatic additive formed by combining more than four organic acids.
In the experiment, the malic acid is selected as a main component, and other metabolites are distributed and mixed with the malic acid to form six compositions and seven metabolites for bacteriostasis test, and the results are shown in table 6.
Figure BDA0003302385110000092
TABLE 6
The results show that even if six or more metabolites are mixed, the bacteriostatic effect on staphylococcus aureus and enterobacter coli can reach the MIC value of 0.1C.
Further, the metabolite combinations comprising malic acid, hippuric acid, fumaric acid and glycine were tested for Escherichia coli, Staphylococcus metalens, Pseudomonas aeruginosa and Serratia marcescens, and the results are shown in Table 7:
Figure BDA0003302385110000101
TABLE 7
The results show that the organic acid metabolite composition consisting of malic acid, hippuric acid, fumaric acid and glycine has an MIC value of 0.1C for Escherichia coli and Staphylococcus aureus and an MIC value of 0.2C for Pseudomonas aeruginosa and Serratia marcescens. The organic acid metabolite composition comprising malic acid, hippuric acid, fumaric acid and glycine has growth inhibiting effect on bacteria represented by Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa and Serratia marcescens, especially pathogenic bacteria.
Serratia marcescens, which is the smallest bacterium, belongs to gram-negative bacilli and is a conditional pathogen.
Pseudomonas aeruginosa is a gram-negative bacterium, and is an opportunistic infectious bacterium.
Escherichia coli, staphylococcus metal, pseudomonas aeruginosa and serratia marcescens are widely distributed in nature, can enter a human body through the positions of the mouth, the nose and the like of the human body, and cause the human body to generate pathogenic reactions such as inflammation and the like under certain conditions or environmental conditions. Therefore, the four strains are selected as test objects of the bacteriostasis test in the experiment.
Based on the experimental results, the composition consisting of malic acid, glycine and hippuric acid can form an effect of inhibiting the bacteria of staphylococcus aureus and escherichia coli to achieve an MIC value of 0.1C together with citric acid or fumaric acid.
The ratio of the composition for experiment can be 0.1% for fumaric acid, 0.4% for succinic acid, 1.3% for L-valine, 1.2% for malic acid, 0.2% for citric acid, 0.1% for glycine and 0.3% for hippuric acid, and the antibacterial composition can be prepared according to the above ratio.
Preferably, the composition for reducing the tendency of microorganisms present on the surface of the human body or in the environment in which the human body is located to multiply comprises: 0.125-0.482% of malic acid, 0.135-0.422% of L-valine, 0.021-0.081% of citric acid, 0.01-0.04% of succinic acid, 0.031-0.121% of hippuric acid, 0.001-0.041% of glycine and 0.01-0.041% of fumaric acid.
Preferably, the ratio of the components in the composition can be: 1 to 30 percent of malic acid, 0.1 to 20 percent of L-valine, 0.1 to 20 percent of citric acid, 0.1 to 20 percent of succinic acid, 0.1 to 20 percent of hippuric acid, 0.1 to 20 percent of glycine and 0.1 to 20 percent of fumaric acid.
Preferably, the ratio of the components in the composition can be: malic acid accounts for 10-40% of the total composition, L-valine accounts for 0.01-10% of the total composition, citric acid accounts for 0.01-10% of the total composition, succinic acid accounts for 0.01-20% of the total composition, hippuric acid accounts for 0.01-20% of the total composition, glycine accounts for 0.01-20% of the total composition, and fumaric acid accounts for 0.01-10% of the total composition.
Preferably, the malic acid can be in the range of about 0.1% to about 20%, about 1% to about 10%, about 3% to about 8%, about 6% to about 12%, about 15% to about 18%, about 17% to about 20%, 20% to 60% by weight, or about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 30%, or about 40% by weight, including all ranges and subranges therebetween, in the total composition.
Preferably, the L-valine can range from about 0.01% to about 1%, about 1% to about 10%, about 3% to about 8%, about 6% to about 12%, about 15% to about 18%, about 17% to about 20% by weight, or about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 30%, or about 40% by weight, including all ranges and subranges therebetween, in the total composition.
Preferably, the citric acid can range from about 0.01% to about 2%, about 1% to about 10%, about 3% to about 8%, about 6% to about 12%, about 15% to about 18%, about 17% to about 20% by weight, or about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 30%, or about 40% by weight, including all ranges and subranges therebetween, in the total composition.
Preferably, the succinic acid can range from about 0.1% to about 20%, about 1% to about 10%, about 3% to about 8%, about 6% to about 12%, about 15% to about 18%, about 17% to about 20% by weight, or about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 30%, or about 40% by weight, including all ranges and subranges therebetween, in the total composition.
Preferably, the hippuric acid can range from about 0.1% to about 20%, about 1% to about 10%, about 3% to about 8%, about 6% to about 12%, about 15% to about 18%, about 17% to about 20%, 20% to 60% by weight, or about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 30%, or about 40% by weight of the total composition, including all ranges and subranges therebetween.
Preferably, the glycine can range from about 0.1% to about 2%, about 1% to about 10%, about 3% to about 8%, about 6% to about 12%, about 15% to about 18%, about 17% to about 20% by weight, or about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 30%, or about 40% by weight, including all ranges and subranges therebetween, in the total composition.
Preferably, the fumaric acid can range from about 0.01% to about 20%, about 1% to about 10%, about 3% to about 8%, about 6% to about 12%, about 15% to about 18%, about 17% to about 20% by weight, or about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 30%, or about 40% by weight, including all ranges and subranges therebetween, in the total composition.
Preferably, the combined range of malic acid, L-valine, citric acid, succinic acid, hippuric acid, glycine and fumaric acid can include, but is not limited to, the above-mentioned ratio and combined range.
The composition having an inhibitory effect against escherichia coli with an MIC value of 0.1C is represented by a composition of malic acid, hippuric acid and citric acid, while the composition having an inhibitory effect against escherichia coli and staphylococcus aureus with an MIC value of 0.1C is represented by malic acid, fumaric acid, glycine, hippuric acid; malic acid, citric acid, glycine, hippuric acid. Since all the components forming the composition are weakly acidic components and can be absorbed by the human body as food additives, the above-mentioned multi-group composition can be applied to various fields as components harmless to the human body. In the prior art, the methods and cognition using organic acids are: any organic acid has the bacteriostatic action, and the organic acid can be added into food or other disinfecting liquid contacting with human body in large dose within the legal allowance and has the bacteriostatic action. However, when used in large quantities as an additive, organic acids generate conversion products in the body, a small amount of the organic acids depends on metabolism, but a large amount of the organic acids cannot ensure that all the products can be metabolized out of the body in time, so that the large amount of the organic acids can cause harm to the body of the human body within a certain period of time. According to the invention, the optimal bacteriostatic composition is obtained by carrying out the bacteriostatic proportion on the organic acid which can effectively inhibit bacteria, and the addition amount of the edible organic acid can be reduced by increasing the variety of the edible organic acid, so that the food or other food is helped to form the influence on the health of a human body while the preservative effect is ensured.
Example 2
This embodiment is a further improvement of embodiment 1, and repeated contents are not described again.
Take the Liyan tablet for chronic pharyngitis treatment at present as an example. Aiming at chronic pharyngitis caused by bacterial infection, the sore throat relieving tablet can have a good effect on the disease. The ingredients of the sore throat relieving tablet comprise pangolin (prepared), ground beeltle, stiff silkworm, oyster (calcined) and figwort, and the pangolin (prepared) in the ingredients is a forbidden medicine because the pangolin (prepared) is taken from endangered organisms, so that the sore throat relieving tablet can not be used as a prescription medicine or a non-prescription medicine for treating patients. According to the invention, by researching the inhibition effect on flora in squama Manis, especially on Escherichia coli and Staphylococcus aureus, one or more groups of compositions with effective inhibition effect on Escherichia coli and Staphylococcus aureus are found. The main components of the medicine comprise: one or more of malic acid, hippuric acid, fumaric acid, glycine, succinic acid, L-valine and citric acid. When the pangolin scales of the liyan tablet are replaced, on one hand, the replacement components can adopt biological tissue extracts with similar components, and on the other hand, the replacement components can also be metabolite replacement components which are synthesized by people and effectively inhibit bacteria. Preferably, when an artificially synthesized compound is used as the substitute component, it can be a composition designed in this experiment to have one of the most excellent inhibitory effects on gram-negative bacteria represented by escherichia coli and gram-positive bacteria represented by staphylococcus aureus: malic acid, fumaric acid, succinic acid, L-valine, citric acid and glycine. The addition of the organic acid can bring fruity taste to the tablets, which is popular with children, thereby increasing the enthusiasm of the infants for taking the medicine.
Example 3
This embodiment is a further improvement of embodiment 1 or embodiment 2, and repeated contents are not described again.
The composition can be used in various foods as additive composition for inhibiting Escherichia coli and Staphylococcus aureus in foods. For example, the natural flavor is increased by the proportion of malic acid and citric acid in some natural fruit juice, and the preservative effect is realized by inhibiting the growth of escherichia coli and staphylococcus aureus by matching the fruit juice in vacuum or sealed package. The main components of the additive comprise: one or more of malic acid, hippuric acid, fumaric acid, glycine, succinic acid, L-valine and citric acid. The presence or combination of malic acid and citric acid, respectively, results in an additive having a fruity flavor.
Example 4
This embodiment is a further improvement on embodiment 1, embodiment 2, or embodiment 3, and repeated contents are not repeated.
The composition can also be used for killing bacteria at home or under ordinary living conditions. For example, in the household life, bacteriostatic bacteria maintenance of the environment or bacteriostatic washing of clothes, especially staphylococcus aureus harmful to the human body, is required. The disinfection of alcohol or 84 disinfectant is also harmful to the human body and is not suitable for families with pregnant women or children. The invention can form the liquid disinfectant suitable for families with children or pregnant women based on the composition of the weakly acidic components and other harmless disinfectant components.
The composition of organic acids can be applied as an additive in detergents or bactericides. The composition as additive is used for clothes or environmental bacteriostasis and deodorization. The composition is provided with a first composition comprising a PH modifier and a second composition for increasing the disinfecting effect and time. The first composition comprises any one of two combinations: malic acid, glycine, hippuric acid, citric acid; malic acid, glycine, hippuric acid and fumaric acid. The second composition comprises a hydrocolloid.
Hydrocolloids, which contain polysaccharides and proteins, form a gel network. When the gel network wraps escherichia coli or staphylococcus aureus carried by a target applied by detergent or bactericide, the first composition existing in the hydrocolloid enters the thallus from the thallus based on the pressure of the gel network on the thallus, the first composition and the second composition act together to form organic acid with synergistic effect, and H is released inside the thallus+Thus, the alkaline environment inside the cells is destroyed, and the activity of the cells is inhibited. The first composition is introduced into the hydrocolloid, and acts on the inner part of the thallus of escherichia coli or staphylococcus aureus along with the coating of the hydrocolloid on escherichia coli or staphylococcus aureus carried by a target for applying the detergent or the bactericide.
The molecular diameter of the organic acid used to act on the intracellular environment of the bacterium can be smaller than the diameter of the cell membrane channel of escherichia coli and staphylococcus aureus so that the organic acid molecule can enter the interior of the bacterium cell from the cell membrane channel and destroy the alkaline environment of the interior of the bacterium cell to inhibit the activity of the bacterium cell.
The joint inhibition effect of the escherichia coli and the staphylococcus aureus is realized through the synergistic effect of a first composition consisting of malic acid, glycine and hippuric acid and a second composition consisting of citric acid or fumaric acid.
Example 5
This embodiment is a further improvement on embodiment 1, embodiment 2, embodiment 3, or embodiment 4, and repeated contents are not repeated.
The present invention contemplates a composition for spreading onto a target surface and killing and inhibiting escherichia coli and staphylococcus aureus on the target surface by spraying, atomizing or otherwise forming a small particle gas or liquid.
The composition consists of combined liquid or gas particles. The liquid or gas particles comprise a particle core consisting of organic acid with high bacteriostasis effect and an outer coating film which is covered on the particle core and consists of a zirconium oxide-tin oxide complex with a nano-grade inorganic micropore form neutralized by a silane coupling agent and is used for protecting and increasing the adhesion capability.
By dispersing the zirconium oxide-tin oxide complex in the form of nano-scale inorganic micropores neutralized by the silane coupling agent wrapping the organic acid in the manner of aerosol, aerosol or small-particle liquid in clothes and living environment, when the zirconium oxide-tin oxide complex in the form of nano-scale inorganic micropores neutralized by the silane coupling agent wrapping the organic acid touches escherichia coli and staphylococcus aureus on the target surface, the outer membrane releases organic acid under pressure and allows the organic acid to enter the bacteria body through the cell membrane on the bacteria surface, thereby inhibiting the bacterial activity. The nano-scale inorganic micropores formed by the zirconia-tin oxide composite can allow organic acid molecules to enter and exit and limit the obstruction of the decomposition and attachment of the particles by large-volume particles. The zirconia-tin oxide composite can effectively maintain the hardness of the outer coating film and the toughness of preventing the collapse of nano-micropores when the outer coating film of particles existing in the form of aerosol, liquid or gas is formed.
Preferably, the ratio of the silane coupling agent to the nano-inorganic microporous zirconia-tin oxide composite is 1:40 to 1: 120. The ratio of the nano-inorganic microporous zirconium oxide-tin oxide composite to the organic acid is 1:1 to 1: 10.
Microparticles composed of organism-inorganic bodies coupled with a silane coupling agent can move toward a target surface in a state of a diameter of at least less than 10 μm. The above microparticles have excellent dispersion stability in an aqueous phase for dilution or homogeneous liquid phase, a high adhesion rate of the organic acid carried on the target surface, and a high volatility of the organic acid core reduced by the coating of the outer membrane. The organic-inorganic hybrid membrane is characterized in that an intermediate phase which is low in cost and can stably couple an internal organic layer and an external inorganic layer is utilized, the inorganic layer which is coupled with the organic layer and does not generate other chemical reactions is added under the condition of not damaging the dissociation of hydrogen ions of the organic layer, and the problems of poor adhesion, no effect and volatility of the organic layer on a target surface are solved through the property of the inorganic layer. Preferably, the silane coupling agent coupling can be an aqueous silane coupling agent coupling.
The preparation method of the composition comprises the following steps:
(1) weighing: weighing the silane coupling agent coupling and zirconia-tin oxide composite (which can be present in the form of a sol) in proportion by weight, and weighing the organic acid composition in terms of volume;
(2) mixing: putting the zirconium oxide and tin oxide complex into organic acid in batches, uniformly mixing, slowly pouring a silane coupling agent along with stirring action for coupling, and stirring until three phases are uniform to obtain the concentrated composition.
The concentrated composition can be diluted with water before use, and sprayed to the target surface to be sterilized such as environment or clothes by using equipment such as an aerosol sprayer and a spray can.
The organic acid in the particle core can be combined with the organic acid which is related in the embodiment and can achieve the bacteriostasis effect on escherichia coli and staphylococcus aureus and the MIC of which is 0.1C. The organic acid composition wrapped by the outer involucra has good stability in water and has high-efficiency inhibition effect on escherichia coli and staphylococcus aureus.
Example 6
This embodiment is a further improvement on embodiment 1, embodiment 2, embodiment 3, embodiment 4, or embodiment 5, and repeated contents are not repeated.
Aiming at the organic acid composition which can be permanently attached to the surface and acts on bacteria, the invention can design a bacteriostatic ointment or spray with one or more of malic acid, hippuric acid, fumaric acid, glycine, succinic acid, L-valine and citric acid, and the bacteriostatic ointment or spray can act on the skin surface or mucous membrane of the face, the arms, important organs and the like. The organic acid composition has obvious antibacterial effect on the multiplication of various pathogenic skin bacteria such as gram-negative bacteria and gram-positive bacteria represented by escherichia coli and staphylococcus aureus.
Preferably, the antibacterial ointment comprises traditional Chinese medicine ointment, traditional Chinese medicine powder, mussel mucin and an organic acid composition containing one or more of malic acid, hippuric acid, fumaric acid, glycine, succinic acid, L-valine and citric acid.
Preferably, the bacteriostatic spray comprises pentanediol, 1, 3-propanediol and an organic acid composition containing one or more of malic acid, hippuric acid, fumaric acid, glycine, succinic acid, L-valine and citric acid.
It should be noted that the above-mentioned embodiments are exemplary, and that those skilled in the art, having benefit of the present disclosure, may devise various arrangements that are within the scope of the present disclosure and that fall within the scope of the invention. It is to be understood by persons skilled in the art that the present description is illustrative and not restrictive of the claims. The scope of the invention is defined by the claims and their equivalents. The present description contains several inventive concepts, such as "preferably", "according to a preferred embodiment" or "optionally", each indicating that the respective paragraph discloses a separate concept, the applicant reserves the right to submit divisional applications according to each inventive concept. Throughout this document, the features referred to as "preferably" are only an optional feature and should not be understood as necessarily requiring that such applicant reserves the right to disclaim or delete the associated preferred feature at any time.

Claims (10)

1. A composition for use on the human body or in an environment in which the human body is located, capable of reducing the tendency of microorganisms present in said environment to multiply, said composition comprising: one or more of malic acid, hippuric acid, fumaric acid, glycine, succinic acid, L-valine and citric acid.
2. The composition according to claim 1, wherein said composition is formed from a first component consisting of malic acid, hippuric acid, succinic acid, L-valine, and a second component consisting of fumaric acid or succinic acid, wherein said first component and said second component are formulated together to provide an inhibitory effect on microbial growth.
3. Composition according to claim 1 or 2, characterized in that said composition acting on the human body or on the environment comprises malic acid, hippuric acid, glycine and citric acid, wherein the composition is capable of enhancing the fruit-fragrant ingredient for acting on the environment based on the interaction of malic acid and citric acid.
4. A composition according to any one of claims 1 to 3, characterized in that it comprises at least malic acid, hippuric acid, glycine and citric acid, wherein the components constituting said composition are applied to the skin surface in the form of a non-newtonian fluid.
5. The composition according to any one of claims 1 to 4, wherein the composition comprises at least malic acid, hippuric acid, glycine and fumaric acid, and wherein the components constituting the composition are applied to the skin surface in the form of a non-Newtonian fluid.
6. The composition according to any one of claims 1 to 5, wherein the composition is capable of inhibiting the proliferation of gram-positive and gram-negative bacteria in a synergistic manner.
7. A composition capable of constituting a cleansing ingredient of an oral cleanser together with an abrasive in the form of a dispersed phase, for inhibiting the growth of gram-negative and gram-positive bacteria represented by escherichia coli and staphylococcus aureus inside an oral cavity, wherein the composition comprises one or more of malic acid, hippuric acid, fumaric acid, glycine, succinic acid, L-valine, and citric acid.
8. A composition capable of inhibiting the proliferation of gram-negative and gram-positive bacteria represented by Escherichia coli and Staphylococcus aureus on the surface of human skin or in food, wherein the composition comprises one or more of malic acid, hippuric acid, fumaric acid, glycine, succinic acid, L-valine and citric acid.
9. Antibacterial use of a composition, characterized in that it is applied as an additive in a detergent or bactericide, said composition as an additive being provided with means for releasing H+And a second composition for increasing the killing effect and time, the first composition comprising: one or more of malic acid, hippuric acid, fumaric acid, glycine, succinic acid, L-valine and citric acid, the second composition comprises hydrocolloid, wherein,
the first composition intervenes in the second composition at the time of application of the composition as an additive, and acts on the inside of the cells of gram-negative and gram-positive bacteria represented by Escherichia coli and Staphylococcus aureus carried by the second composition to the target of detergent or bactericide application.
10. Antibacterial use of a composition, characterized by a medicament for bacterial infections, said medicament comprising as essential components: one or more of malic acid, hippuric acid, fumaric acid, glycine, succinic acid, L-valine and citric acid.
CN202111195294.4A 2021-10-13 2021-10-13 Composition and antibacterial application thereof Active CN113995744B (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202111195294.4A CN113995744B (en) 2021-10-13 2021-10-13 Composition and antibacterial application thereof
LU102887A LU102887B1 (en) 2021-10-13 2021-12-16 Composition and antibacterial usage thereof
PCT/CN2022/124947 WO2023061416A1 (en) 2021-10-13 2022-10-12 Composition and antibacterial use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111195294.4A CN113995744B (en) 2021-10-13 2021-10-13 Composition and antibacterial application thereof

Publications (2)

Publication Number Publication Date
CN113995744A true CN113995744A (en) 2022-02-01
CN113995744B CN113995744B (en) 2023-03-17

Family

ID=79922851

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111195294.4A Active CN113995744B (en) 2021-10-13 2021-10-13 Composition and antibacterial application thereof

Country Status (3)

Country Link
CN (1) CN113995744B (en)
LU (1) LU102887B1 (en)
WO (1) WO2023061416A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115466652A (en) * 2022-09-21 2022-12-13 云南水星生物科技有限公司 Antibacterial color fixative and preparation method and application thereof
WO2023061416A1 (en) * 2021-10-13 2023-04-20 温州肯恩大学 Composition and antibacterial use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001028339A2 (en) * 1999-10-19 2001-04-26 The Procter & Gamble Company Antimicrobial compositions comprising a biologically active organic acid
JP2006526594A (en) * 2003-06-05 2006-11-24 ピュラック バイオケム ビー． ブイ． Antibacterial composition comprising a mixture of lactic acid or its derivative and inorganic acid
KR20130123489A (en) * 2012-05-03 2013-11-13 이상현 Microbicide compositions using vitamin b1 derivatives and effective microorganism
KR101976709B1 (en) * 2018-08-08 2019-05-09 주식회사 세니젠 Antimicrobial composition with malic acid, citric acid and phytic acid
CN111225564A (en) * 2017-10-16 2020-06-02 株式会社日本抗菌总和研究所 Antibacterial composition
US20200397849A1 (en) * 2017-11-17 2020-12-24 Renovion, Inc. Stable ascorbic acid compositions and methods of using the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3253207T3 (en) * 2015-02-05 2020-05-18 Hygienix Bv Method for disinfecting a surface, and composition suitable for use therein
CN107212236A (en) * 2017-06-26 2017-09-29 苏州凌科特新材料有限公司 A kind of composite biological preservative and preparation method thereof
CN108904374A (en) * 2018-07-24 2018-11-30 常州市嘉乐钢板网制造有限公司 Cleaning agent for mouth cavity
CN113995744B (en) * 2021-10-13 2023-03-17 温州肯恩大学 Composition and antibacterial application thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001028339A2 (en) * 1999-10-19 2001-04-26 The Procter & Gamble Company Antimicrobial compositions comprising a biologically active organic acid
JP2006526594A (en) * 2003-06-05 2006-11-24 ピュラック バイオケム ビー． ブイ． Antibacterial composition comprising a mixture of lactic acid or its derivative and inorganic acid
KR20130123489A (en) * 2012-05-03 2013-11-13 이상현 Microbicide compositions using vitamin b1 derivatives and effective microorganism
CN111225564A (en) * 2017-10-16 2020-06-02 株式会社日本抗菌总和研究所 Antibacterial composition
US20200397849A1 (en) * 2017-11-17 2020-12-24 Renovion, Inc. Stable ascorbic acid compositions and methods of using the same
KR101976709B1 (en) * 2018-08-08 2019-05-09 주식회사 세니젠 Antimicrobial composition with malic acid, citric acid and phytic acid

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
张军等: "有机酸抑菌分子机理研究进展", 《畜牧兽医学报》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023061416A1 (en) * 2021-10-13 2023-04-20 温州肯恩大学 Composition and antibacterial use thereof
CN115466652A (en) * 2022-09-21 2022-12-13 云南水星生物科技有限公司 Antibacterial color fixative and preparation method and application thereof

Also Published As

Publication number Publication date
CN113995744B (en) 2023-03-17
LU102887B1 (en) 2022-12-01
WO2023061416A1 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
CN109316536A (en) A kind of skin mucosa disinfecting agent and preparation method thereof
WO2023061416A1 (en) Composition and antibacterial use thereof
CN110075036A (en) Anti- oral helicobacter pylori medicated toothpaste
CN104688648B (en) A kind of composition for oral cavity and preparation method thereof
TWI538682B (en) The use of the extract toon
CN116036137A (en) Antibacterial and antiviral drug, antibacterial and antiviral component, and method for producing antibacterial and antiviral drug
CN109077945A (en) Combined bacteriostat with lysozyme for cosmetics
CN108042578A (en) A kind of health care vaginal jellies containing compound probiotic ingredient
CN102389743A (en) Formula of medical bacteriostatic humidifying solution
CN111493097A (en) Collective disinfectant for inhibiting viruses and pathogenic bacteria and preparation method thereof
CN1367018A (en) Compound preparation of staphylococcolysis enzyme and its preparation method and application
CN106511114A (en) Broad spectrum bactericidal pure natural orange extract essence and preparation method thereof
CN111671816A (en) Plant type no-clean antibacterial disinfectant and preparation method thereof
KR102251911B1 (en) Silver ion bacteriostatic hand sanitizer and preparation method and application thereof
CN104886165A (en) Compound air disinfectant and preparation method thereof
CN111328811B (en) Low-concentration alcohol sterilization disinfectant and application thereof
CN104000767B (en) A kind of Feminine care solution and preparation method thereof
CN104338168A (en) Air freshener for upper respiratory infection patients and preparing method thereof
CN113599343A (en) Traditional Chinese medicine daily chemical product with antibacterial effect and preparation method thereof
CN103720815A (en) Degerming agent specially used for silver carp breeding
CN106420938A (en) Traditional Chinese medicine composition for curing oral inflammation and pharyngitis and preparation method of traditional Chinese medicine composition
CN110433117A (en) Mouthwash and preparation method thereof
CN102698302B (en) Dedicated vegetal air disinfectant for medical institution
CN110892895A (en) Negative ion antibacterial composition, preparation method and application
CN107802799A (en) A kind of Medical antiseptic solution

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20230801

Address after: Workstation 11, Wenzhou Ken University Creative Space, No. 88 Daxue Road, Li'ao Street, Ouhai District, Wenzhou City, Zhejiang Province, 325000

Patentee after: Wenzhou Lien Biotechnology Co.,Ltd.

Address before: 325060 No. 88, University Road, Ouhai District, Wenzhou City, Zhejiang Province

Patentee before: Wenzhou-Kean University

TR01 Transfer of patent right